BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Sep 06, 2010
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Mipomersen: Additional Phase III data

Additional data from the double-blind, North American Phase III RADICHOL II trial in 124 patients showed that once-weekly subcutaneous injections of 200 mg mipomersen significantly reduced APOB by 26% from baseline to week 26 vs. a 7% increase for placebo (p<0.001). Mipomersen also significantly reduced total cholesterol and non-HDL cholesterol by 19% and 25%, respectively, vs. a 4% increase in both measures for placebo (p<0.001 for both). Additionally, mipomersen significantly reduced lipoprotein(a) (LPA) by 21% vs. no change for placebo (p<0.001). Patients were already receiving a maximally-tolerated dose...

Read the full 427 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >